Use of Monoclonal Antibodies Therapy for Treatment of Mild to Moderate COVID-19 in 4 Patients with Rheumatologic Disorders

BACKGROUND: The use of monoclonal antibodies therapy (MAT) in early mild to moderate Coronavirus disease 2019 (COVID-19) has gained importance in recent times. However, there is limited information on the safety and efficacy of MAT in treating COVID-19 in patients with underlying rheumatologic disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Franchin, Giovanni, Mantri, Nikhitha, Zahid, Maleeha, Sun, Haozhe, Gongati, Sudharsan R., Ronderos, Diana M., Gadireddy, Snigdha, Chilimuri, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631366/
https://www.ncbi.nlm.nih.gov/pubmed/34819488
http://dx.doi.org/10.12659/MSM.934267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631366/
https://www.ncbi.nlm.nih.gov/pubmed/34819488
http://dx.doi.org/10.12659/MSM.934267

Ejemplares similares